iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
The Lancet Oncology.
Times cited: 405
Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study.
Times cited: 708
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
Journal of Clinical Oncology.
Times cited: 217
- Gefitinib. Drugs. 2002 Comment GET IT